Sign in to view content

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results

David A. Eichenbaum, MD, FASRS

Video
Published 2020

Related

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study
J. Fernando Arevalo, MD, PhD, FACS, FASRS
Updates from the Field
2020
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Matthew Starr, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more